New Cloud-Based system could transform diabetes care in hospitals

NCT ID NCT05307237

Completed Disease control Sponsor: Scripps Whittier Diabetes Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a continuous glucose monitor (CGM) that sends real-time blood sugar data to a cloud-based dashboard, allowing a remote team to manage high-risk type 2 diabetes patients in the hospital. Over 500 participants were assigned to either the active CGM system or usual care with blinded monitoring. The goal was to improve time in safe blood sugar range and reduce hospital infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexcom G6 Continuous Glucose Monitor (device)
What this could lead to: If successful, this could lead to better blood sugar management and fewer infections for hospitalized diabetes patients, especially those with limited access to care.
What could go wrong: This is a completed study, but results may not apply to all hospitals or patient groups. The device requires proper training and may have technical issues or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Scripps Mercy Hospital

Chula Vista, California, 91910, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.